IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
TPI Enterprises Ltd v Tasmanian Alkaloids Pty Ltd [2018] APO 8
Patent Application: 2009253741
Title:Papaver somniferum with high concentration of codeine
Patent Applicant: Tasmanian Alkaloids Pty Ltd
Opponent: TPI Enterprises Ltd
Delegate: Dr S. J. Smith
Decision Date: 31 January 2018
Hearing Date: 15 June 2017 in Canberra
Catchwords: PATENTS – opposition to the grant of a patent – grounds of manner of manufacture and inventive step – not established that the claims encompass naturally-occurring subject matter – manner of manufacture ground not successful – inventive step – expectation of success not established – inventive step ground not successful – costs awarded against opponent
Representation: Counsel for the applicant: Ms Katrina Howard SC
Patent attorney for the applicant: Dr Charles Tansey of Shelston IP
Counsel for the opponent: Mr Gerard Dalton QC
Solicitor for the opponent: Mr Zaven Mardirossian and Ms Claire Southwell of Arnold Bloch Leibler
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Application: 2009253741
Title:Papaver somniferum with high concentration of codeine
Patent Applicant: Tasmanian Alkaloids Pty Ltd
Date of Decision: 31 January 2018
DECISION
The opposition is unsuccessful. Subject to appeal of this decision or Sun Pharmaceutical Industries (Australia) Pty Ltd v Tasmanian Alkaloids Pty Ltd [2018] APO 7 I direct that the application proceed to grant.
I award costs according to Schedule 8 against TPI Enterprises Ltd.
REASONS FOR DECISION
Background
Patent application 2009253741 was filed by Tasmanian Alkaloids Pty Limited (TasAlk) on 28 May 2009 under the provisions of the Patent Cooperation Treaty. The application claims priority from US 61/056,880, US 61/160,532 and US 61/160,749, which were filed on 29 May 2008, 16 March 2009 and 17 March 2009, respectively.
Acceptance of the application was advertised on 11 June 2015. TPI Enterprises Ltd (TPI) filed a notice of opposition under section 59 on 7 September 2015 and a hearing was held in Canberra on 15 June 2017. This decision relates to the opposition by TPI. Sun Pharmaceutical Industries (Australia) Pty Ltd also opposed grant of the application and the decision in relation to that opposition is reported as Sun Pharmaceutical Industries (Australia) Pty Ltd v Tasmanian Alkaloids Pty Ltd [2018] APO 7 (the Sun opposition).
TasAlk proposed post-acceptance amendments to the specification on 22 April 2016 which were allowed unopposed on 17 August 2016. This decision is in relation to the specification as amended.
The Opposition
The statement of grounds and particulars was filed on 11 December 2015 and set out the following grounds of opposition: manner of manufacture, inventive step and fair basis. Manner of manufacture and inventive step were pressed at the hearing, with manner of manufacture limited to the particular basis that the claims include naturally-occurring subject matter. An amended statement of grounds and particulars reflecting those grounds was filed on 20 June 2017 and the amendment allowed on 21 July 2017.
Evidence
The evidence filed during the evidentiary periods is summarised in the table below:
Evidence Declarant Exhibits Date of declaration Reference In…
Keep reading for free
Create a free CaseChat account to read TPI Enterprises Ltd v Tasmanian Alkaloids Pty Ltd and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2018] APO 8
- Decision Date
CaseChat Overview and Summary
Orders
Orders of the court
Full text does not contain this section.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.